Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel study drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven

Next Previous
Trial Profile

A Phase 1b/2 study for patients with triple-negative breast cancer and baseline insulin resistance, testing the novel study drug evexomostat (SDX-7320) in combination with standard-of-care treatment Halaven

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary) ; Evexomostat (Primary)
  • Indications Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors SynDevRx, Inc

Most Recent Events

  • 06 Jun 2022 New trial record
  • 01 Jun 2022 According to a SynDevRx media release, the clinical research study is being conducted in collaboration with New York's Memorial Sloan Kettering Cancer Center (MSK).
  • 01 Jun 2022 According to a SynDevRx media release, Dr. Neil Iyengar, MD, an MSK breast medical oncologist and principal investigator of this study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top